...
首页> 外文期刊>Health policy and planning >With the help of a foreign ally: Biopharmaceutical innovation in India after TRIPS
【24h】

With the help of a foreign ally: Biopharmaceutical innovation in India after TRIPS

机译:在外国盟友的帮助下:TRIPS之后印度的生物制药创新

获取原文
获取原文并翻译 | 示例

摘要

This article investigates the implications of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which reached full-fledged implementation in 2005, for the patenting activity of Indian biopharmaceutical companies. The Indian biopharmaceutical industry is well-known for its generic producers, whose business models capitalize on the opportunity to reverse-engineer patented compounds and produce them at low costs through process innovation. By strengthening intellectual property rights, TRIPS determined a major regulative change, which presents the characteristics of an institutional shock. The examination of the patenting and alliance activity of 123 Indian biopharmaceutical firms between 1999 and 2009 reveals two important insights. First, the innovation outcome of Indian biopharmaceuticals has sharply increased during the transition to TRIPS-compliant regulation, suggesting that Indian companies have been capable and willing to transit from an imitation-based to an innovation-based business model. Second, those biopharmaceutical firms holding cross-border alliances to foreign partners have proved significantly more successful at enhancing their innovative capability. This research delivers a multifold contribution to the policy debate surrounding the enforcement of TRIPS in emerging economies. First, it suggests that such regulatory change may have encouraged biopharmaceutical innovation in India, despite the sceptical voices who did not foresee any benefits because of inherent inertia of the industry. Second, by arguing and testing the advantages of foreign partnerships, this research highlights that the much feared return of pharmaceutical foreign companies to India could instead favour adaptation to institutional change. Implications for Indian public health are particularly critical. The impact of TRIPS on drug pricing and on the capability-and willingness-of Indian biopharmaceuticals to invest in local health conditions are two crucial points of discussion.
机译:本文研究了与贸易有关的知识产权协议(TRIPS)的含义,该协议于2005年全面实施,对印度生物制药公司的专利活动产生了影响。印度生物制药行业以其仿制药生产商而闻名,其仿制药生产商利用了对专利化合物进行逆向工程并通过工艺创新以低成本生产的机会。通过加强知识产权,TRIPS确定了一项重大的法规变更,这体现了制度冲击的特征。对1999年至2009年间123家印度生物制药公司的专利和联盟活动进行的检查揭示了两个重要见解。首先,在向符合TRIPS的法规过渡期间,印度生物制药的创新成果急剧增加,这表明印度公司已经有能力并且愿意从基于模仿的商业模式过渡到基于创新的商业模式。第二,事实证明,那些与外国合作伙伴建立跨境联盟的生物制药公司在增强创新能力方面取得了显着的成功。这项研究为围绕新兴市场经济体TRIPS执法的政策辩论做出了多方面的贡献。首先,它表明这种监管变化可能鼓励了印度的生物制药创新,尽管怀疑的声音由于该行业的固有惯性并未预见到任何好处。其次,通过争论和检验外国合伙企业的优势,这项研究突出表明,外国制药企业最担心返回印度的做法反而会有利于适应体制变革。对印度公共卫生的影响尤为关键。 TRIPS对药品定价以及印度生物药品投资于当地健康状况的能力和意愿的影响是讨论的两个关键点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号